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Mast cell infiltrates are associated with tumors, though
their role in the tumor microenvironment remains
unclear. Mast cells express high levels of KIT through-
out differentiation and as mature cells. Mast cells in
tumors have been shown to release proinflammatory
cytokines and promote angiogenesis, increasing tumor
growth and metastasis. KIT signaling and mast cells also
appear to modulate myleloid-derived suppressor cell
(MDSC) development, recruitment and activity in
tumors. Furthermore, treatment of tumor-bearing mice
or cancer patients with small molecule KIT inhibitors or
an anti-mouse KIT antibody decreased tumoral MDSCs
and other immunosuppressive cells including regulatory
T cells. KTN0158 is a humanized anti-KIT IgG1 mono-
clonal antibody that specifically binds KIT and is being
developed as a potential therapy for cancer and mast
cell-related diseases such as neurofibromatosis type 1
(NF1). It binds canine, feline, non-human primate and
human KIT with high affinity, but does not bind mouse
or rat KIT. KTN0158 inhibits KIT signaling and function
in vitro and in vivo and has shown antitumor activity in
dogs with mast cell tumors expressing either wild-type or
mutant KIT. Immune checkpoint inhibitors targeting the
CTLA-4 and PD-1 pathways have demonstrated single
agent efficacy in cancer patients, and the combinations
have shown superior efficacy in some preclinical and
clinical settings. To test the effects of KIT inhibition on
immune tolerance in syngeneic mouse tumor models, the
anti-mouse KIT monoclonal antibody ACK2 was used as
a surrogate for KTN0158 and tested alone and in combi-
nation with CTLA-4 and PD-1 inhibitors. In the Colon26
model, single agent treatment with the anti-KIT antibody
had little antitumor activity. However, the combination of
anti-KIT and anti-CTLA-4 had substantial antitumor
effects, comparable to those observed for anti-CTLA-4 plus
anti-PD1. These antitumor effects were dose-dependent.
Pharmacodynamic assessments will also be presented.
Collectively, these data suggest that the combination of
immunotherapies targeting KIT on innate immune cells
and checkpoint pathway inhibitors may have clinical
benefit.
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